{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:01:34Z","timestamp":1791284494207,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HA 8790\/3-1"],"award-info":[{"award-number":["HA 8790\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KR 3886\/7-1"],"award-info":[{"award-number":["KR 3886\/7-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HA 8790\/3-1"],"award-info":[{"award-number":["HA 8790\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KR 3886\/7-1"],"award-info":[{"award-number":["KR 3886\/7-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01384-9","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:18:42Z","timestamp":1760962722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2988-8483","authenticated-orcid":false,"given":"M.","family":"Korenkov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7547-1222","authenticated-orcid":false,"given":"J.","family":"Liebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0902-0369","authenticated-orcid":false,"given":"S.","family":"Yousefian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-5793","authenticated-orcid":false,"given":"S.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6480-4185","authenticated-orcid":false,"given":"U. M.","family":"Demel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2026-2641","authenticated-orcid":false,"given":"J.","family":"Braune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Odabasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Herzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"B\u00f6ckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-2461","authenticated-orcid":false,"given":"N. C.","family":"G\u00f6r\u00fcr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"v. Landenberg-Roberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tregel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5609-2472","authenticated-orcid":false,"given":"C.","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9227-2051","authenticated-orcid":false,"given":"S.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-1958","authenticated-orcid":false,"given":"U.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-6947","authenticated-orcid":false,"given":"A.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"1384_CR1","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer JN. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol. 2024;24:830\u201345.","journal-title":"Nat Rev Immunol"},{"key":"1384_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01167-8","volume":"14","author":"GG Fortuna","year":"2024","unstructured":"Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Mor\u00e1n-Segura CM, Nguyen JV, et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024;14:180.","journal-title":"Blood Cancer J"},{"key":"1384_CR3","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales M-A, Cordas Dos Santos DM, et al. Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5517 lymphoma and myeloma patients. Clin Cancer Res. 2024;30:4690\u2013700.","journal-title":"Clin Cancer Res"},{"key":"1384_CR4","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of Parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27:2099\u2013103.","journal-title":"Nat Med"},{"key":"1384_CR5","unstructured":"Lim KJC, Parrondo R, Chhabra S, Dooley K, Corraes ADS, Gertz M, et al. Diagnosis, predictors and outcomes for immune effector cell associated enterocolitis in multiple myeloma patients receiving cilta-cel. EHA Library: Milan, 2025 https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4161226\/kenneth.jin.chang.lim.diagnosis.predictors.and.outcomes.for.immune.effector.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Asearch%3Dchimeric."},{"key":"1384_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood.2023021429","volume":"142","author":"CE Graham","year":"2023","unstructured":"Graham CE, Lee W-H, Wiggin HR, Supper VM, Leick MB, Birocchi F, et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity. Blood. 2023;142:1248\u201352.","journal-title":"Blood"},{"key":"1384_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, G\u00e1llego P\u00e9rez-Larraya J, Van De Donk NWCJ, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:32.","journal-title":"Blood Cancer J"},{"key":"1384_CR8","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1212\/WNL.0000000000210768","volume":"104","author":"L Miller","year":"2025","unstructured":"Miller L, Barrell K. Peripheral and cranial neuropathies following CAR-T cell therapy for multiple myeloma: a case series (S16.006). Neurology. 2025;104:3063.","journal-title":"Neurology"},{"key":"1384_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.hlife.2024.05.005","volume":"2","author":"W Zhang","year":"2024","unstructured":"Zhang W, Liu D, Zhang T, Cao J, Wang G, Li H, et al. BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy. hLife. 2024;2:434\u20138.","journal-title":"hLife"},{"key":"1384_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06916-6","volume":"626","author":"L S\u00faken\u00edkov\u00e1","year":"2024","unstructured":"S\u00faken\u00edkov\u00e1 L, Mallone A, Schreiner B, Ripellino P, Nilsson J, Stoffel M, et al. Autoreactive T cells target peripheral nerves in Guillain\u2013Barr\u00e9 syndrome. Nature. 2024;626:160\u20138.","journal-title":"Nature"},{"key":"1384_CR11","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","volume":"26","author":"CE Graham","year":"2025","unstructured":"Graham CE, Velasco R, Alarcon Tomas A, Stewart OP, Dachy G, Del Bufalo F, et al. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Oncol. 2025;26:e203\u201313.","journal-title":"Lancet Oncol"},{"key":"1384_CR12","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1182\/blood-2024-201783","volume":"144","author":"AD Kumar","year":"2024","unstructured":"Kumar AD, Atallah-Yunes SA, Rajeeve S, Abdelhak A, Hashmi H, Corraes A, et al. Delayed neurotoxicity after CAR-T in multiple myeloma: results from a global IMWG registry. Blood. 2024;144:4758.","journal-title":"Blood"},{"key":"1384_CR13","doi-asserted-by":"publisher","first-page":"71.e1","DOI":"10.1016\/j.jtct.2024.12.002","volume":"31","author":"M Ellithi","year":"2025","unstructured":"Ellithi M, Elsallab M, Lunning MA, Holstein SA, Sharma S, Trinh JQ, et al. Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS Data. Transplant Cell Ther. 2025;31:71.e1\u201371.e14.","journal-title":"Transplant Cell Ther"},{"key":"1384_CR14","doi-asserted-by":"crossref","unstructured":"Geraghty AC, Acosta-Alvarez L, Rotiroti MC, Dutton S, O\u2019Dea MR, Kim W, et al. Immunotherapy-related cognitive impairment after CAR T cell therapy in mice. Cell. 2025;188:3238-3258.e25.","DOI":"10.1016\/j.cell.2025.03.041"},{"key":"1384_CR15","doi-asserted-by":"crossref","unstructured":"Kelly K, Cooperrider J, Bishop MR, Kosuri S, Jakubowiak A, Derman BA. Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025;9:3613\u20136.","DOI":"10.1182\/bloodadvances.2024015721"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01384-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:18:43Z","timestamp":1760962723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01384-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01384-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AB: Received honoraria not related to this manuscript from Novartis, Kite, MSD, AstraZeneca, and Takeda, as well as travel grants from Gilead, Takeda, and Janssen. JK: Advisory role, consulting, and travel support from Johnson & Johnson.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Clinical data were retrospectively collected from health records following institutional approval (Ethikkommission der Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin: EA2\/142\/20). Informed consent was obtained from all participants. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"168"}}